pyruvic acid has been researched along with MELAS Syndrome in 8 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
MELAS Syndrome: A mitochondrial disorder characterized by focal or generalized seizures, episodes of transient or persistent neurologic dysfunction resembling strokes, and ragged-red fibers on muscle biopsy. Affected individuals tend to be normal at birth through early childhood, then experience growth failure, episodic vomiting, and recurrent cerebral insults resulting in visual loss and hemiparesis. The cortical lesions tend to occur in the parietal and occipital lobes and are not associated with vascular occlusion. VASCULAR HEADACHE is frequently associated and the disorder tends to be familial. (From Joynt, Clinical Neurology, 1992, Ch56, p117)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was diagnosed with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS)." | 7.72 | Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS): a mitochondrial disorder presents as fibromyalgia. ( Cardenas, RJ; De la Fuente, FA; DeSouza, RA; Lindler, TU; Mayorquin, FJ; Trochtenberg, DS, 2004) |
| "The long-term effects of the sodium salt of dichloroacetic acid (DCA) were evaluated in four patients with mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes (MELAS) carrying A3243G mutation." | 5.11 | Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. ( Goto, T; Momoi, MY; Mori, M; Saito, S; Yamagata, T, 2004) |
| " A 48-week, prospective, single-centre, exploratory, clinical study enrolled 11 Japanese adult patients with genetically, biochemically, and clinically confirmed mitochondrial disease; they had intractable lactic acidosis and received SP (0." | 3.91 | Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. ( Inoue, E; Koga, Y; Nashiki, K; Povalko, N; Tanaka, M, 2019) |
| " The patient was diagnosed with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS)." | 3.72 | Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS): a mitochondrial disorder presents as fibromyalgia. ( Cardenas, RJ; De la Fuente, FA; DeSouza, RA; Lindler, TU; Mayorquin, FJ; Trochtenberg, DS, 2004) |
| "Clinical features of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) resemble those of cerebral infarcts, but the pathogenesis of infarct-like lesions is not fully understood." | 3.70 | Serial diffusion-weighted imaging in MELAS. ( Imon, Y; Kajima, T; Katayama, S; Mimori, Y; Nakamura, S; Ohshita, T; Oka, M; Watanabe, C; Yamaguchi, S, 2000) |
| "The diagnosis of mitochondrial disorders (MDs) is occasionally difficult because patients often present with solitary, or a combination of, symptoms caused by each organ insufficiency, which may be the result of respiratory chain enzyme deficiency." | 1.42 | Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. ( Arahata, H; Fujita, Y; Fukumoto, Y; Ishii, A; Ito, M; Kakuma, T; Koga, Y; Kojima, T; Saiki, R; Tanaka, M; Yatsuga, S, 2015) |
| "Children with MELAS had various clinical manifestations." | 1.39 | [Clinical, pathological and molecular biological characteristics of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episode in children]. ( Bao, XH; Chang, XZ; Liu, XL; Ma, YN; Qin, J; Wu, XR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, Y | 2 |
| Povalko, N | 1 |
| Inoue, E | 1 |
| Nashiki, K | 1 |
| Tanaka, M | 3 |
| Liu, XL | 1 |
| Bao, XH | 1 |
| Ma, YN | 1 |
| Chang, XZ | 1 |
| Qin, J | 1 |
| Wu, XR | 1 |
| Yatsuga, S | 1 |
| Fujita, Y | 2 |
| Ishii, A | 1 |
| Fukumoto, Y | 1 |
| Arahata, H | 1 |
| Kakuma, T | 1 |
| Kojima, T | 1 |
| Ito, M | 2 |
| Saiki, R | 1 |
| Kami, K | 1 |
| Igarashi, S | 1 |
| Koike, S | 1 |
| Sugawara, S | 1 |
| Ikeda, S | 1 |
| Sato, N | 1 |
| Tomita, M | 1 |
| Soga, T | 1 |
| DeSouza, RA | 1 |
| Cardenas, RJ | 1 |
| Lindler, TU | 1 |
| De la Fuente, FA | 1 |
| Mayorquin, FJ | 1 |
| Trochtenberg, DS | 1 |
| Mori, M | 1 |
| Yamagata, T | 1 |
| Goto, T | 1 |
| Saito, S | 1 |
| Momoi, MY | 1 |
| Dunbar, DR | 1 |
| Moonie, PA | 1 |
| Zeviani, M | 1 |
| Holt, IJ | 1 |
| Ohshita, T | 1 |
| Oka, M | 1 |
| Imon, Y | 1 |
| Watanabe, C | 1 |
| Katayama, S | 1 |
| Yamaguchi, S | 1 |
| Kajima, T | 1 |
| Mimori, Y | 1 |
| Nakamura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GDF-15 as a Biomarker for Mitochondrial Disease[NCT02745938] | 97 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyruvic acid and MELAS Syndrome
| Article | Year |
|---|---|
Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Chemical and Drug Induced Liver Injury; Child; Dic | 2004 |
7 other studies available for pyruvic acid and MELAS Syndrome
| Article | Year |
|---|---|
Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease.
Topics: Acidosis, Lactic; Adolescent; Adult; Biomarkers; Female; Fibroblast Growth Factors; Growth Different | 2019 |
[Clinical, pathological and molecular biological characteristics of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episode in children].
Topics: Acidosis, Lactic; Adolescent; Brain; Child; Child, Preschool; DNA Mutational Analysis; DNA, Mitochon | 2013 |
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders.
Topics: Adolescent; Adult; Biomarkers; Child; Creatine Kinase; Female; Fibroblast Growth Factors; Growth Dif | 2015 |
Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations.
Topics: Cell Line; DNA, Mitochondrial; Electrophoresis, Capillary; Energy Metabolism; Humans; MELAS Syndrome | 2012 |
Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS): a mitochondrial disorder presents as fibromyalgia.
Topics: Aged; Diagnosis, Differential; Female; Fibromyalgia; Humans; Lactic Acid; MELAS Syndrome; Muscle, Sk | 2004 |
Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids.
Topics: Cell Fusion; DNA, Mitochondrial; Electron Transport Complex IV; Humans; Hybrid Cells; Lactates; Lact | 1996 |
Serial diffusion-weighted imaging in MELAS.
Topics: Adult; Atrophy; Brain; DNA, Mitochondrial; Echo-Planar Imaging; Female; Humans; Lactic Acid; Magneti | 2000 |